Enzymatic Production Of A Protein Or Polypeptide (e.g., Enzymatic Hydrolysis, Etc.) Patents (Class 435/68.1)
  • Patent number: 10377825
    Abstract: The invention provides anti-HER2 antibodies, including anti-HER2 antibodies of improved stability or affinity, and methods of using the same.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: August 13, 2019
    Assignee: Genentech, Inc.
    Inventors: Mary Mathieu, Mark Dennis
  • Patent number: 10377699
    Abstract: A method for the synthesis of daptomycin or a daptomycin analog is carried out on a resin to form a linear precursor followed by a serine ligation macrocyclization in solution. Daptomycin analogs can differ from daptomycin by substitution of amino acids residues and/or deletion or addition of amino acid residues. Daptomycin analogs can include a different fatty acid in the side arm of the daptomycin analog.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: August 13, 2019
    Assignee: The University of Hong Kong
    Inventors: Xuechen Li, Hiu Yung Lam
  • Patent number: 10358470
    Abstract: The object of the present invention is to provide a glycosylated polypeptide having uniform sugar chain structure which has interferon ? activity. It was found that a glycosylated polypeptide having uniform sugar chain structure as well as having interferon ? activity can be prepared by a method comprising a step of synthesizing a glycosylated peptide fragment and at least two peptide fragments and a step of linking the glycosylated peptide fragment and the at least two peptide fragments.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: July 23, 2019
    Assignee: GLYTECH, INC.
    Inventors: Izumi Sakamoto, Kazuhiro Fukae, Katsunari Tezuka, Keisuke Tazuru, Masatoshi Maeda, Yasuhiro Kajihara, Takashi Tsuji
  • Patent number: 10308716
    Abstract: The invention relates to a method for producing polyclonal antibodies against an antigenic target protein which comprises inducing an immune response in a host by applying an immunogenic composition comprising membrane vesicles incorporating said antigenic target protein to said host and obtaining antibodies against said target protein from the host's serum.
    Type: Grant
    Filed: September 24, 2014
    Date of Patent: June 4, 2019
    Assignee: Fraunhofer-Gesellschaft zur Foerderung der angewandten Forschung e. V.
    Inventors: Marlitt Stech, Katja Hanack, Katrin Messerschmidt, Stefan Kubick
  • Patent number: 10278047
    Abstract: In one embodiment a method for providing presence information in a smart environment is implemented on a personal computing device associated with a user and includes: broadcasting a presence indicator signal in the smart environment, where the presence indicator signal indicates presence of the user in the smart environment, and the personal computing device is not provided by an operator of the smart environment.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: April 30, 2019
    Assignee: Cisco Technology, Inc.
    Inventors: David C. White, Jr., Magnus Mortensen, Jay Kemper Johnston, Rama Darbha
  • Patent number: 10259856
    Abstract: Novel acylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H.
    Type: Grant
    Filed: April 14, 2015
    Date of Patent: April 16, 2019
    Assignee: Novo Nordisk A/S
    Inventors: Peter Madsen, Thomas Boerglum Kjeldsen, Thomas Hoeg-Jensen, Palle Jakobsen, Tina Moeller Tagmose, Tine Glendorf, Janos Tibor Kodra, Patrick William Garibay, Jacob Sten Petersen
  • Patent number: 10259909
    Abstract: The present invention discloses a method for preparing glatiramer acetate, comprising: (1) dissolving L-alanine NCA, L-tyrosine NCA, L-glutamic acid-?-benzyl ester NCA, and L-?-trifluoroacetyl-lysine NCA in 1,4-dioxane as solvent, stirring until a clarified solution is formed; (2) adding diethylamine for catalysis, stirring at 20-25° C., then slowly pouring the reaction solution into water, collecting the produced white product; (3) adding the obtained product to a solution of hydrobromic acid in acetic acid, stirring at 23.0-25.0° C., pouring the reaction solution into purified water for quenching and stirring, subjecting the mixture to suction filtration to obtain a yellow solid, after repeating 3-5 times, subjecting the solid to blast drying to remove the moisture therein; and (4) dissolving the solid obtained in step (3) in a 1M piperidine aqueous solution at room temperature and stirring, subjecting the obtained solution to dialysis, adding glacial acetic acid to adjust the pH to 5.5-7.
    Type: Grant
    Filed: November 26, 2015
    Date of Patent: April 16, 2019
    Assignee: HYBIO PHARMACEUTICAL CO., LTD.
    Inventors: Huixing Yuan, Guotao Li, Jian Liu, Yaping Ma, Jiancheng Yuan
  • Patent number: 10190145
    Abstract: The present disclosure describes methods and systems for improving the expression of a properly folded, biologically active protein of interest in a cell free synthesis system. The methods and systems use a bacterial cell free extract having an active oxidative phosphorylation system, and include an exogenous protein chaperone. The exogenous protein chaperone can be expressed by the bacteria used to prepare the cell free extract. The exogenous protein chaperone can be a protein disulfide isomerase and/or a peptidyl-prolyl cis-trans isomerase. The inventors discovered that the combination of a protein disulfide isomerase and a peptidyl-prolyl cis-trans isomerase produces a synergistic increase in the amount of properly folded, biologically active protein of interest.
    Type: Grant
    Filed: April 18, 2014
    Date of Patent: January 29, 2019
    Assignee: Sutro Biopharma, Inc.
    Inventors: Alice Yam, Dan Groff, Patrick Rivers, Christopher D. Thanos
  • Patent number: 10172407
    Abstract: A safety helmet that provides improved protection against injuries that can result from both linear and angular head acceleration is described. The helmet features an outer shell, an interface structure and a liner. The liner is a matrix structure formed from silkworm cocoons. Minimization of weight and sustainability, without compromising functionality, are also features of the helmet.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: January 8, 2019
    Assignee: New York University
    Inventors: Howard A. Riina, Fritz Vollrath
  • Patent number: 10138509
    Abstract: Methods of making a three-dimensional matrix of nucleic acids within a cell is provided.
    Type: Grant
    Filed: February 26, 2014
    Date of Patent: November 27, 2018
    Assignee: President and Fellows of Harvard College
    Inventors: George M. Church, Je-Hyuk Lee, Richard C. Terry, Evan R. Daugharthy
  • Patent number: 10106690
    Abstract: The present invention provides a surface-independent surface-modifying multifunctional biocoating and methods of application thereof. The method comprises contacting at least a portion of a substrate with an alkaline solution comprising a surface-modifying agent (SMA) such as dopamine so as to modify the substrate surface to include at least one reactive moiety. In another version of the invention, a secondary reactive moiety is applied to the SMA-treated substrate to yield a surface-modified substrate having a specific functionality.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: October 23, 2018
    Assignee: NORTHWESTERN UNIVERSITY
    Inventors: Phillip B. Messersmith, Haeshin Lee
  • Patent number: 10087236
    Abstract: Modified Fc regions of antibodies and antibody fragments, both human and humanized, and having enhanced stability and efficacy, are provided. Fc regions with core fucose residues removed, and attached to oligosaccharides comprising terminal sialyl residues, are provided. Antibodies comprising homogeneous glycosylation of Fc regions with specific oligosaccharides are provided. Fc regions conjugated with homogeneous glycoforms of monosaccharides and trisaccharides, are provided. Methods of preparing human antibodies with modified Fc using glycan engineering, are provided.
    Type: Grant
    Filed: December 2, 2010
    Date of Patent: October 2, 2018
    Assignee: ACADEMIA SINICA
    Inventors: Chi-Huey Wong, Chung-Yi Wu
  • Patent number: 9988413
    Abstract: The present invention discloses one pot process for the conversion of hemicellulose into C5 sugars using ionic liquids in water media.
    Type: Grant
    Filed: January 21, 2015
    Date of Patent: June 5, 2018
    Assignee: COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH
    Inventors: Paresh Laxmikant Dhepe, Babasaheb Mansub Matsagar
  • Patent number: 9976133
    Abstract: Novel synthetic catalytic structures or “synzymes,” e.g., synthetic polypeptides, with catalytic properties are provided. It is believed that these synthetic catalytic structures mimic some of the precise conformational changes necessary for catalytic activities seen in enzymes. The catalytic properties of these synthetic catalytic structures or synzymes can be further improved by the application of controlled external forces, e.g., electric fields.
    Type: Grant
    Filed: June 20, 2013
    Date of Patent: May 22, 2018
    Assignee: The Regents of the University of California
    Inventors: Michael J. Heller, Tsukasa Takahashi, Michelle Lillian Cheung
  • Patent number: 9950075
    Abstract: The invention in some aspects provides compounds useful for targeting bacterial infections. In some embodiments, the compounds comprise a transferrin receptor ligand covalently linked to a bactericidal agent. In some embodiments, the bactericidal agent is a bactericidal peptide, such as a glycoside hydrolase (e.g., lysozyme).
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: April 24, 2018
    Assignee: The University of Massachusetts
    Inventors: Son N. Nguyen, Cedric E. Bobst, Igor A. Kaltashov
  • Patent number: 9926353
    Abstract: The present invention is directed to polymerized products and compositions useful for the treatment and prevention of amyloid disease in a subject. The invention further relates to isolated antibodies that recognize a common conformational epitope of amyloidogenic proteins or peptides that are useful for the diagnosis, treatment, and prevention of amyloid disease.
    Type: Grant
    Filed: July 16, 2012
    Date of Patent: March 27, 2018
    Assignee: New York University
    Inventors: Thomas M. Wisniewski, Fernando Goni
  • Patent number: 9908064
    Abstract: A portable fluidic platform for rapid and flexible end-to-end production of recombinant protein biologics includes a bioreactor system hosting stable and robust cell-free translation systems that is fluidically integrated with modular protein separation functionalities (e.g., size exclusion, ion exchange or affinity chromatography systems) for purification of the cell-free expressed product and which are configurable for process-specific isolation of different proteins, as well as for formulation. The bioreactor utilizes lysates from engineered eukaryotic (e.g., yeast) or prokaryotic (e.g., bacterial) strains that contain factors for protein folding and posttranslational modifications. Combination of various purification modules on the same fluidic platform allows flexibility of re-routing for purification of different proteins depending on specific target requirements.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: March 6, 2018
    Assignee: Leidos, Inc.
    Inventors: John Dresios, Richard Holmes Griffey, Challise J. Sullivan, Erik D. Pendleton, Henri M. Sasmor, William L. Hicks, Eric M. Amendt
  • Patent number: 9782436
    Abstract: Disclosed herein are flowable tissue matrix compositions comprising small pieces of partially or completely decellularized tissue suspended in a gelatinized tissue or gelatin gel comprising partially or completely decellularized tissue or synthetic gelatin. The flowable tissue matrix compositions can contain factors that promote or enhance native cell migration, proliferation, and/or revascularization after implantation into a subject. Also disclosed are methods of making and using the flowable tissue matrix compositions. The compositions can be implanted into a tissue in need of repair, regeneration, healing, treatment, and/or alteration, and can promote or enhance native cell migration, proliferation, and/or revascularization.
    Type: Grant
    Filed: April 23, 2013
    Date of Patent: October 10, 2017
    Assignee: LifeCell Corporation
    Inventor: Wenquan Sun
  • Patent number: 9757495
    Abstract: Methods for preparing and using collagen extracts and collagen scaffolds are provided. Additionally methods and related kits for the repair of articular tissue using the collagen material are provided.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: September 12, 2017
    Assignee: Children's Medical Center Corporation
    Inventor: Martha M. Murray
  • Patent number: 9650433
    Abstract: Sulfated glycoproteins, and methods of making and using such sulfated glycoproteins, are described.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: May 16, 2017
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Dorota A. Bulik, Carlos J. Bosques, Brian Edward Collins, Maurice Gaston Hains, Nathaniel J. Washburn, James Meador, Sean Smith, Naveen Bhatnagar
  • Patent number: 9617299
    Abstract: A method of purifying a fusion protein, including: (1) adjusting the pH of an aqueous phase, containing a fusion protein which is a fusion of a protein having a self-assembly capability and a tamet protein, and which aqueous phase has a first pH, to a second pH, to obtain a remaining aqueous phase and a solid fraction containing an amount of the fusion protein; (2) separating the solid fraction from the remaining aqueous phase, to obtain a separated solid fraction; and (3) dissolving the separated solid fraction in a solution having a pH of 12 or lower but higher than the second pH by at least 0.1 pH units, wherein the protein having a self-assembly capability is a cell surface protein.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: April 11, 2017
    Assignee: AJINOMOTO CO., INC.
    Inventors: Takahiro Nonaka, Teruhisa Mannen, Noriko Tsurui
  • Patent number: 9617300
    Abstract: An excellent peptidyl peptidase-IV inhibitor and the like are provided. A peptide consisting of Val-Pro-X wherein X represents an amino acid residue (except for L-proline residue); the aforementioned X is preferably one selected from a basic amino acid residue, an aliphatic neutral amino acid residue, an amide group-carrying neutral amino acid residue, or an aromatic group-carrying neutral amino acid residue; the aforementioned X is preferably one selected from an alanine residue, a glutamine residue, a methionine residue, an asparagine residue, a glycine residue, a valine residue, a tyrosine residue, a serine residue, and a lysine residue; a dipeptidyl peptidase-IV inhibitor, a blood sugar rise suppressing agent, a vascular endothelial disorder suppressing agent, and an angiotensin converting enzyme inhibitor containing the aforementioned peptide as an active ingredient.
    Type: Grant
    Filed: February 21, 2013
    Date of Patent: April 11, 2017
    Assignee: MORINAGA MILK INDUSTRY CO., LTD.
    Inventors: Akio Yamada, Takuma Sakurai, Daisuke Ochi
  • Patent number: 9611183
    Abstract: The present invention relates to production of inorganic fertilizers and biomass fiber suitable for thermal conversion processes. A method of producing biomass fiber for thermal conversion processes and inorganic mineral fertilizer from source biomass, includes mixing size reduced source biomass and a fluid under conditions favorable for extracting inorganic nutrients from the size reduced source biomass. A liquid extract phase and a solid phase are separated from the mixture. The liquid extract phase is then concentrated to obtain the inorganic fertilizer. The solid phase is dried to obtain biomass fiber for thermal conversion processes.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: April 4, 2017
    Assignee: BIOLINE CORPORATION
    Inventors: Mohamad Mogharab-Rahbari, Nicholas Ivan Ruzich
  • Patent number: 9597346
    Abstract: The present invention provides a method of reducing levels of at least one target protein in a cell. The cell is contacted with a first agent and a second agent. The first agent reduces synthesis of the target protein, e.g., by reducing levels of the mRNA of the target protein or inhibits translation of the mRNA. The second agent accelerates degradation of the target protein. The first agent may contact the cell before, after or simultaneously with the second agent. The first agent and the second agent may be in separate delivery vehicles, or in a single delivery vehicle. The first agent may be an RNAi (RNA interference) molecule, such as a small interfering RNA (siRNA), a small hairpin RNA (shRNA) or a microRNA (miRNA). The second agent may be a chimeric polypeptide containing a ubiquitin ligase polypeptide and a target protein interacting domain. The ubiquitin ligase polypeptide can be an E3 ubiquitin ligase, including, but not limited to, an SCF polypeptide, a HECT polypeptide and a UBR1 polypeptide.
    Type: Grant
    Filed: January 17, 2011
    Date of Patent: March 21, 2017
    Assignee: Cornell University
    Inventor: Pengbo Zhou
  • Patent number: 9540610
    Abstract: The invention relates to the use of an active collagen matrix for culturing mammalian cells and the use of the active collagen matrix and cells for the treatment of disease.
    Type: Grant
    Filed: April 28, 2011
    Date of Patent: January 10, 2017
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: Abdulhafez A. Selem, Lawrence A. Shimp, Hsiu Ying Sherry Wang
  • Patent number: 9528137
    Abstract: Cell-free protein synthesis systems and methods of using the same for producing in vitro protein materials in high yield are disclosed. The cell-free protein synthesis platform includes (a) a Saccharomyces cerevisiae cellular extract prepared from mid-exponential to late-exponential batch cultures in the range from about 6 OD600 to about 18 OD600 or fed-batch cultures harvested in mid-exponential to late-exponential phase; (b) a reaction buffer; and (c) a translation template or (c?) a transcription template from which a translation template can be prepared in situ with an RNA polymerase. A method of performing high-throughput protein synthesis in vitro is also provided that utilizes a combined transcription/translation reaction with the cell-free protein synthesis platform from Saccharomyces cerevisiae, an RNA polymerase and a transcription template prepared from a source DNA using an amplification procedure.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: December 27, 2016
    Assignee: Northwestern University
    Inventors: Michael C. Jewett, Charles E. Hodgman, Rui Gan
  • Patent number: 9526770
    Abstract: Disclosed herein, in certain instances, are methods of inhibiting osteoclast differentiation, bone resorption, bone formation, and bone remodeling in an individual in need thereof, comprising administering to the individual a composition comprising substantially fetal support tissue product including amniotic membrane and umbilical cord or an extract thereof, or a composition comprising substantially isolated HC-HA complex.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: December 27, 2016
    Assignee: TISSUETECH, INC.
    Inventors: Scheffer Tseng, Ek Kia Tan, Hua He
  • Patent number: 9511012
    Abstract: A composition is disclosed that includes pure silk fibroin-based protein fragments that are substantially devoid of sericin, wherein the composition has an average weight average molecular weight ranging from about 17 kDa to about 38 kDa, wherein the composition has a polydispersity of between about 1.5 and about 3.0, wherein the composition is substantially homogeneous, wherein the composition between 0 ppm to about 500 ppm of inorganic residuals, and wherein the composition includes between 0 ppm to about 500 ppm of organic residuals.
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: December 6, 2016
    Assignee: Silk Therapeutics, Inc.
    Inventors: Gregory H. Altman, Rebecca L. Horan, Rachel Lee Dow, Rachel M. Lind, Dylan S. Haas
  • Patent number: 9499783
    Abstract: A sugar solution production apparatus includes a saccharification tank that obtains a saccharified solution containing a solid substance from a cellulose-containing biomass, a solid-liquid separator that separates the solid substance from the saccharified solution to obtain a sugar solution, an enzyme recovery solution tank that stores an enzyme recovery solution, a sugar solution extraction line that extracts the sugar solution from the solid-liquid separator, a warm water supply unit that supplies warm water to the solid-liquid separator, an enzyme recovery solution supply line that supplies the enzyme recovery solution from the enzyme recovery solution tank to the solid-liquid separator, an enzyme recovery solution recovery line that feeds the enzyme recovery solution containing the saccharifying enzyme recovered from the solid substance to the enzyme recovery solution tank, and an enzyme recovery solution return line that returns the enzyme recovery solution to the saccharification tank.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: November 22, 2016
    Assignee: Toray Industries, Inc.
    Inventors: Atsushi Minamino, Junpei Kishimoto, Hiroyuki Kurihara, Katsushige Yamada
  • Patent number: 9487771
    Abstract: The invention relates to new method of peptide hydrolysis, in particular of the cell walls of Gram-positive bacteria, wherein the active form of LytM or derivative thereof is contacted with a peptide substrate, preferably with the cell walls of Gram-positive bacteria, in an aqueous environment of conductivity lower than 10 mS/cm. The invention also relates to composition comprising active form of LytM or derivative thereof and new uses of active form of LytM or derivative thereof.
    Type: Grant
    Filed: October 17, 2013
    Date of Patent: November 8, 2016
    Assignee: MIEDZYNARODOWY INSTYTUT BIOLOGII MOLEKULARNEJ I KOMORKOWEJ
    Inventors: Izabela Sabala, Matthias Bochtler
  • Patent number: 9464109
    Abstract: A method for the introduction of a labeling structure such as fluorescent molecules or a Raman tag to a compound is described. Imidazole functionalized resins or polymers are used to selectively immobilize phosphocompounds without protecting the carboxylic groups is described. Relying on the pKa difference between amines and hydrazides and carrying out the reaction in a slightly acidic buffer, all of the amines are protected by protonation while the hydrazides react with the phosphate imidazolide to form a phosphoramidate bond.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: October 11, 2016
    Assignee: INTEL CORPORATION
    Inventors: Handong Li, Narayan Sundararajan
  • Patent number: 9458446
    Abstract: The present invention relates to polypeptides having endopeptidase activity and to methods of producing and using the polypeptides. The invention also relates to methods of making a food protein hydrolysate using a trypsin-like endopeptidase derived from a bacterium.
    Type: Grant
    Filed: September 30, 2011
    Date of Patent: October 4, 2016
    Assignee: NOVOZYMES A/S
    Inventors: Peter Rahbek Oestergaard, Carsten P. Sonksen, Tine Hoff, Gitte B. Lynglev
  • Patent number: 9410170
    Abstract: Improved methods are provided in vitro synthesis of biological molecules, providing for improved yields, lowered costs, and enhanced utility. Improved yield and lowered cost is obtained by the use of a phosphate free energy source in the presence of exogenous phosphate, and optionally in the absence of exogenous nucleoside triphosphates.
    Type: Grant
    Filed: November 18, 2004
    Date of Patent: August 9, 2016
    Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Kara Calhoun, Michael Christopher Jewett, James Robert Swartz
  • Patent number: 9393267
    Abstract: The present invention discloses methods and compositions comprising a biocompatible gel that is used in tissue repair and regeneration. Once the gel is administered to a tissue site in need of repair or regeneration, the cells migrate from the gel into the tissue and repair or regenerate the tissue.
    Type: Grant
    Filed: February 19, 2010
    Date of Patent: July 19, 2016
    Assignee: University of Southern California
    Inventors: Bo Han, Kenrick Kuwahara
  • Patent number: 9386789
    Abstract: The present invention provides a brewed soy sauce that has light color and reduced smell with a robust taste. In the brewed soy sauce, HEMF is less than 15 ppm. Glutamic acid is 0.9% (w/v) or more. Lactic acid and acetic acid are respectively 0.1% (w/v) or more. Reducing sugar is 1.5% (w/v) or less. Levulinic acid is less than 0.01% (w/v). And, pH is 4.5-5.5. The brewed soy sauce is produced as follows: First, a raw material is prepared from a plant protein-source material and a low-starch carbohydrate-source material. Then, koji is made by inoculating koji mold to the prepared raw material. Next, salt water is added to the koji, and the mixture of the salt water and koji is fermented. At least 5 days after initiating the fermentation, yeast belonging to Candida genus is added to the mixture. Then, the fermentation is matured.
    Type: Grant
    Filed: May 30, 2014
    Date of Patent: July 12, 2016
    Assignee: YAMASA CORPORATION
    Inventors: Yoshiyuki Toyoshima, Yoshinobu Mogi, Kaori Miura
  • Patent number: 9388370
    Abstract: A substrate or coating is provided that includes a protease with enzymatic activity toward a component of a biological stain. Also provided is a process for facilitating the removal of a biological stain is provided wherein an inventive substrate or coating including a protease is capable of enzymatically degrading of one or more components of the biological stain to facilitate biological stain removal from the substrate or said coating.
    Type: Grant
    Filed: August 6, 2012
    Date of Patent: July 12, 2016
    Assignees: Toyota Motor Engineering & Manufacturing North America, Inc., Toyota Motor Corporation
    Inventors: Songtao Wu, Hongfei Jia, Masahiko Ishii, Minjuan Zhang
  • Patent number: 9382564
    Abstract: A method of diversification of human milk oligosaccharides (HMOs) or precursors thereof, compounds obtainable by the method, and uses and compositions involving such compounds. The method comprises a) providing at least one compound or a mixture of the compounds selected from the group consisting of: optionally sialylated and/or fucosylated lactose derivatives of general formula 2 and salts thereof; b) adding at least one enzyme comprising a transglycosidase activity to the at least one compound or a mixture of compounds provided according to step a); and c) incubating the mixture obtained according to step b).
    Type: Grant
    Filed: May 14, 2012
    Date of Patent: July 5, 2016
    Assignee: GLYCOM A/S
    Inventors: Gyula Dekany, Elise Champion, Andreas Schroven, Markus Hederos
  • Patent number: 9365881
    Abstract: The current invention comprises a method for producing an immunoglobulin or immunoglobulin fragment or immunoglobulin fusion with G1 glycostructure comprising incubating with a galactosyltransferase, a sialyltransferase, a beta-1,4-galactosidase and a sialidase, whereby the galactosyltransferase is added in more than one aliquot during the incubating.
    Type: Grant
    Filed: October 2, 2012
    Date of Patent: June 14, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Martina Hueller, Dietmar Reusch
  • Patent number: 9347050
    Abstract: The invention provides mannosidases capable of uncapping mannose-1-phospho-6-mannose moieties and demannosylating phosphorylated N-glycans, methods of using such mannosidases, glycoproteins produced using the methods, as well as methods of facilitating mammalian cellular uptake of glycoproteins.
    Type: Grant
    Filed: September 29, 2011
    Date of Patent: May 24, 2016
    Assignee: Oxyrane UK Limited
    Inventors: Kathleen Camilla Telesphore Alida Maria Piens, Wouter Vervecken, Albena Vergilieva Valevska, Gwenda Noëlla Pynaert
  • Patent number: 9328172
    Abstract: The invention is a methodology which makes it possible to select from a very large number of cells, a single cell or cells of interest and obtain specific information from those cells in a rapid and efficient manner. As an example of the methodology, a large number of antibody producing cells such as plasma cells are separated so that these individual antibody producing plasma cells are placed in individual wells. The cells are allowed to produce antibodies and the antibodies in the wells are then contacted with a protein bound to a solid surface such as a well top. The protein universally and specifically binds antibodies in the wells. The surface or well tray top includes addresses configured such that each address is specifically related to one of the individual wells containing a cell producing antibodies.
    Type: Grant
    Filed: April 3, 2009
    Date of Patent: May 3, 2016
    Assignee: Single Cell Technology, Inc.
    Inventors: Chun-Nan Chen, James O. Bowlby, Richard Aleck Jorgensen, Mark Jay Shlomchik
  • Patent number: 9289533
    Abstract: Materials and methods for improving the biological properties and electromechanical performance of collagen scaffolds used for cell transplantation, including the fixation of biocompatible reagents and adhesion molecules which control cell adhesion, apoptosis, survival and/or differentiation simultaneously. The grafting of adhesion molecules to collagen matrices renders same suitable for use in vascular and cardiothoracic surgery/medicine, as well as in cell therapy for the heart and in artificial heart muscle engineering. Also, a simple method for grafting and optimising the presentation of adhesion peptides or biological agents when the scaffold is made from collagen and/or contains accessible thiol, amine or carboxyl groups.
    Type: Grant
    Filed: June 10, 2008
    Date of Patent: March 22, 2016
    Inventors: Olivier Schussler, Robert Michelot
  • Patent number: 9290794
    Abstract: A polynucleotide encoding a biosensor polypeptide comprising a modified circularly-permuted thermostable luciferase and a linker linking the C-terminal portion of the thermostable luciferase to the N-terminal portion of the thermostable luciferase. The modified circularly-permuted thermostable luciferase is modified relative to a parental circularly-permuted thermostable luciferase. The linker contains a sensor region capable of interacting with a target molecule in a cell. The modified circularly-permuted thermostable luciferase has an enhanced response after interaction of the biosensor with the target molecule relative to the parental circularly-permuted thermostable luciferase in the presence of the target molecule. Alternatively, the modified circularly-permuted thermostable luciferase has an enhanced response after interaction of the biosensor with the target molecule relative to the modified circularly-permuted thermostable luciferase in the absence of the target molecule.
    Type: Grant
    Filed: November 12, 2012
    Date of Patent: March 22, 2016
    Assignee: PROMEGA CORPORATION
    Inventors: Brock Binkowski, Braeden Butler, Lance P. Encell, Frank Fan, Brad Hook, Paul Otto, Kimberly Risma, Gediminas Vidugiris, Susan Wigdal, Kristopher Zimmerman
  • Patent number: 9267111
    Abstract: Described herein are methods of treating a female subject in need of in vitro fertilization to become pregnant by detecting a loss of non-atretic follicles in the female subject and providing in vitro fertilization to the female subject.
    Type: Grant
    Filed: January 14, 2011
    Date of Patent: February 23, 2016
    Assignee: The General Hospital Corporation
    Inventors: Jonathan L. Tilly, Joshua Johnson
  • Patent number: 9259023
    Abstract: The present invention relates to an enzymatic process for making a milk-based protein hydrolysate and use of such hydrolysate, e.g., in an infant formula composition.
    Type: Grant
    Filed: April 1, 2010
    Date of Patent: February 16, 2016
    Assignee: Novozymes A/S
    Inventors: Peter Rahbek Oestergaard, Steffen Ernst, Gitte B. Lynglev
  • Patent number: 9226953
    Abstract: The invention relates to variants of plasminogen and plasmin comprising one or more point mutations in the catalytic domain which reduce or prevent autocatylic destruction of the protease activity of plasmin. Compositions, uses and methods of using said variants of plasminogen and plasmin are also disclosed.
    Type: Grant
    Filed: July 9, 2010
    Date of Patent: January 5, 2016
    Assignee: ThromboGenics NV
    Inventor: Richard Reinier Zwaal
  • Patent number: 9206233
    Abstract: An approach to synthesizing and assembling nanoparticles into discrete, size-tunable, pre-designed architectures is realized in a single synthetic/process step.
    Type: Grant
    Filed: September 16, 2008
    Date of Patent: December 8, 2015
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Nathaniel L. Rosi, Chun-Long Chen
  • Patent number: 9187543
    Abstract: The present invention relates to the field of recombinant protein production in bacterial hosts. It further relates to extraction of soluble, active recombinant protein from an insoluble fraction without the use of denaturation and without the need for a refolding step. In particular, the present invention relates to a production process for obtaining high levels a soluble recombinant Type 1 interferon protein from a bacterial host.
    Type: Grant
    Filed: March 2, 2011
    Date of Patent: November 17, 2015
    Assignee: PFENEX INC.
    Inventors: Jeffrey Allen, Ping-Hua Feng, Anant Patkar, Keith L. Haney, Lawrence Chew, Lei Lei Phokham Sengchanthalangsy
  • Patent number: 9175327
    Abstract: According to the present invention, a composition possessing cell-free protein synthesis activity with reduced contaminating lipopolysaccharide, and a method for producing a protein using the same are provided. When ribosome display is performed using the composition and method for protein production of the present invention, the background that is caused by non-specific binding is reduced, so that a nucleic acid that encodes the desired polypeptide can be selected with high accuracy and high efficiency.
    Type: Grant
    Filed: May 3, 2011
    Date of Patent: November 3, 2015
    Assignees: GeneFrontier Corporation, The University of Tokyo
    Inventors: Takashi Kanamori, Yuki Hayami, Kanehisa Kojoh, Takuya Ueda, Kumiko Tsuihiji, Tomoe Fuse, Mikiko Nakamura, Shizue Kato
  • Patent number: 9175326
    Abstract: The present invention provides for recombinant Endo-D and selected mutants that exhibit reduced hydrolysis activity and increased transglycosylation activity for the synthesis of glycoproteins wherein a desired sugar chain is added to a core fucosylated or nonfucosylated GlcNAc-protein acceptor by transglycosylation. Such recombinant Endo-D and selected mutants are useful for efficient glycosylation remodeling of IgG1-Fc domain.
    Type: Grant
    Filed: February 5, 2013
    Date of Patent: November 3, 2015
    Assignee: UNIVERSITY OF MARYLAND, BALTIMORE
    Inventor: Lai-Xi Wang
  • Patent number: 9161969
    Abstract: Alveolar macrophages contribute to host defenses against influenza. Enhancing their function contributed to protection against influenza and other acute lethal pulmonary infections. Wild-type mice and Tg mice expressing GM-CSF in the lung were infected with influenza virus, and lung pathology, weight loss and mortality were measured. GM-CSF was also administered to lungs of wild-type mice that were infected with influenza virus. All Tg mice expressing GM-CSF in the lungs survived with greatly reduced weight loss and lung injury and histologic evidence of a rapid host inflammatory response that controlled infection vs. wild-type mice not expressing GM-CSF in the lungs. This resistance to influenza was abrogated by elimination of alveolar phagocytes, but not by depletion of T cells, B cells or neutrophils. Tg mice had far more alveolar macrophages than wild-type mice and were more resistant to influenza-induced apoptosis. Delivery of intranasal GM-CSF to wild-type mice also conferred influenza resistance.
    Type: Grant
    Filed: March 22, 2012
    Date of Patent: October 20, 2015
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventor: Homayoun Shams